In vitro and in vivo activities of clarithromycin against Mycobacterium avium.
There is no effective therapy to treat Mycobacterium avium complex infection in patients with acquired immune deficiency syndrome. Clarithromycin (A-56268; TE-031) is a new macrolide which is twofold more active than erythromycin against most aerobic bacteria. In addition, higher levels in serum and...
Guardat en:
| Publicat a: | Antimicrob Agents Chemother |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Microbiology (ASM)
1989
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC172696/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2530933/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.33.9.1531 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
